Table 1.
Human pluripotent stem cell (hPSC) lines used in this work.
| Cell Line | Passage | Karyotype/CGH | Origin |
|---|---|---|---|
| iPSC lines | |||
| PB3 | 43 | 46, XX | Normal amniocyte |
| PB4 | 26 | 46, XY | Amniocyte, sickle cell anemia |
| PB6 | 23 | 47, XY, +21 | Amniocyte, Down syndrome |
| PB6.1 | 14 | 47, XY, +21 | Amniocyte, Down syndrome |
| PB7 | 63 | 46, XY | Normal amniocyte |
| PB9 | 17 | 46, XY | Normal amniocyte |
| PB10 | 16 | 46, XY | Normal amniocyte |
| PB12.1 | 33 | 47, XY, +21 | Amniocyte, Down syndrome |
| PB13 | 28 | 46, XY | Endothelial progenitor cell from peripheral blood |
| PB14.3 | 41 | 47, XX, +21 | Amniocyte, Down syndrome |
| PB17 | 38 | 46, XY | Endothelial progenitor cell from peripheral blood |
| ESC lines | |||
| SA01 | 22+4+7 | 46, XY | Cellartis AB, Sweden |
| H1 | 67 | 46, XY | WiCell, Wisconsin, USA |
| H9 | 31 | 46, XX | WiCell, Wisconsin, USA |
| CL01 | 16 | 46, XY, der21, t(1;21) | Paris Sud University, France |
All iPSC lines were generated in ESTeam Paris Sud University, Inserm U935, Villejuif, France. CGH, Comparative Genomic Hybridization; der21, t(1;21), unbalanced chromosome translocation involving chromosome 1 and chromosome 21.